# MORM syndrome (<u>m</u>ental retardation, truncal <u>o</u>besity, <u>r</u>etinal dystrophy, and <u>m</u>icropenis), a new autosomal recessive disorder, links to 9q34

Daniel J Hampshire<sup>2,6</sup>, Mohammed Ayub<sup>1,6</sup>, Kelly Springell<sup>2,6</sup>, Emma Roberts<sup>2</sup>, Hussain Jafri<sup>3</sup>, Yasmin Rashid<sup>3</sup>, Jacquelyn Bond<sup>2</sup>, John H Riley<sup>4</sup>, C Geoffrey Woods<sup>5</sup>

<sup>2</sup>Molecular Medicine Unit, University of Leeds, St James's University Hospital, Leeds LS9 7TF, UK. <sup>1</sup>Department of Psychiatry of Learning Disabilities, St Luke's Hospital, Middlesbrough TS4 3AF, UK.

<sup>3</sup>Department of Obstetrics and Gynaecology, Lady Wellington Hospital, Lahore, Pakistan.

<sup>4</sup>Discovery and Pipeline Genetics, GSK, New Frontiers Science Park North, Harlow CM19 5AW, UK.

<sup>5</sup>Department of Medical Genetics, CIMR, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 2BP, UK.

<sup>6</sup>These authors contributed equally to the work.

Address for correspondence and reprints: Dr C G Woods, Department of Medical Genetics, CIMR, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 2BP, UK. Tel 01223 767 81

E-mail: cw347@cam.ac.uk.

# **Key points**

- We describe a noveldisorder, MORM syndrome, the features of which are mild/moderate mental retardation, congenital retinal dystrophy, truncal obesity and in males micropenis.
- We report the locus for this disorder maps to chromosome 9q34.3.
- The minimal critical region spans 0.5 Mb (~1 cM) between SNPs rs3812547 and rs2811742 with a maximum multipoint LOD score of 5.64.
- We believe this to be the first example of the identification of a sub-telomeric recessive locus by autozygosity mapping.

## ABSTRACT

A consanguineous pedigree is described where fourteen individuals are affected with a novel autosomal recessive disorder which causes static moderate mental retardation, truncal obesity, a congenital non-progressive retinal dystrophy and micropenis in males. We have tentatively named this condition MORM syndrome. It shows similarities to Bardet-Biedl syndrome and Cohen syndrome but can be distinguished by clinical features; furthermore linkage to the known Bardet-Biedl (BBS1-8) and Cohen syndrome loci was excluded. Autozygosity mapping identified a single homozygous sub-telomeric region shared by all affecteds on chromosome 9q34.3, with a maximum LOD score of 5.64. We believe this to be the first example of the identification of a sub-telomeric recessive locus by autozygosity mapping.

#### **CLINICAL DETAILS**

Ethical approval for this project was obtained in both the UK and Pakistan. A Northern Pakistani pedigree of 9 sib-ships containing 14 affected individuals was ascertained. The clinical details were based on the information gathered through multiple sources: 1. Interviews with the affected individuals and members of their families. 2. Reports from schools, with informed consent from individuals and families. 3. Historical information about the development gathered from more than one resource, to minimise the chances of recall bias. 4. Intellectual ability assessed by MA who is a trained Learning Disability Psychiatrist and has experience of working both in the UK and Pakistan, speaks the local language, and has a good knowledge of the local cultural norms. 5. Physical development assessed by referring to the norms developed for Pakistan and available in the local clinics.

It was difficult to administer any formal IQ test because these individuals had visual impairment and also there was a limited choice of tests with normative data for the population. The assessment took into consideration the adaptive functioning, the impairment caused by visual impairment, and socio-cultural issues. The criteria specified in The Diagnostic and Statistical Manual of Mental Disorders (DSM IV)[1] was used as a guide for specifying the level of mental retardation. Based on the

experience of mental retardation as it presents in that population these individuals had mild to moderate mental retardation.

The pregnancy and birth of affected individuals was normal, there was no hypotonia and polydactyly or other congenital anomalies were not observed. Poor night vision was evident within the first year of life. By three years of age reduced visual acuity was apparent; however, thereafter no further visual loss occurred. Individuals were able to travel around the village using surroundings and familiarity, and were able to see large shapes and colour. The occurrence of cataracts in most affected individuals in the second or third decade of life lead to a further reduction in visual acuity. Examination showed an mildly atrophic retina with thinned blood vessels but without increased pigmentation or optic atrophy. All had delayed language acquisition and by four years static mild to moderate mental retardation was apparent. Motor milestones were normal and hypotonia and spasticity were not observed. By five years minor truncal obesity was noticeable in affected children, which became more marked in the second decade but neither acanthosis nigricans nor diabetes developed. Males did progress through puberty with appropriate growth gain, development of male hair pattern and testicular growth, but the penis remained at the prepubescent size. Affected males had not been treated with testosterone; therefore it was unclear whether there was an end organ resistance to testosterone. Affected individuals enjoyed good health and had normal growth parameters; however none were known to have born or fathered offspring (Figure 1). Three reputed affected individuals had died of natural causes (infection, accident and heart attack) in the preceding decade at 16y, 25y and 40y respectively.

A simplified family pedigree is shown (Figure 2). The family shows complex consanguinity. The inheritance pattern of the disorder is consistent with autosomal recessive, with both sexes similarly affected and no parent affected. Cytogenetic analysis was normal at 450-850 band quality in two parents and two affected individuals.

The kindred live in a valley in the foothills of the Salt Range, in the Punjab of Northern Pakistan. Family lore has it that sixteen Arabs settled in the valley 1,000 years ago, and that since that time descendants have always married within the "family". The village of the descendants has moved twice since its origins to other locations within the same valley, most recently to its present location 300 years ago to offer greater protection from the marauding of Sikhs in the area at that time. The village currently numbers about 5,000 with five different clans. The pedigree with affected individuals is a subgroup of one of the clans. The condition is only found in this subgroup and all the affected individuals can be traced back to one founding couple. There is a strong tradition of inter-marriage in all the clans and their subgroups.

#### **MOLECULAR GENETICS**

#### Materials / Methods

After obtaining informed consent and Ethical Committee permission blood samples were collected from 14 affected individuals and 8 of their parents from which DNA was extracted using standard methods. To test for linkage to one of the eight BBS or Cohen syndrome loci polymorphic microsatellite markers were selected using published gene / loci data, the Human Genome Browser and the Genome Database.[2][3][4][5][6][7][8][9][10][11] Seven of the affected individuals were genotyped with these markers using standard methods: no evidence of linkage was found (data not shown). Further examination of the eight BBS loci revealed no evidence of triallelic inheritance (data not shown).[12]

A genome wide search for regions of shared homozygosity was performed on the family using the Weber Human Screening Set version 8 (Research Genetics), which contains 385 autosomal microsatellite repeat markers spaced at approximately 10 cM intervals with an average heterozygosity of 0.76. PCR amplification of all markers was performed according to the manufacturer's specifications using a Roboseq 4200 thermal cycler (MWG Biotech Ltd.). Amplified markers were pooled and electrophoresed on an ABI Prism 377 gene sequencer (Applied Biosystems) using 4.2% polyacrylamide gels at 3000V and 51°C for 2.5 hours. Fragment length analysis was conducted using Genescan 3.1.2 and Genotyper 2.5 analysis packages (Applied Biosystems).

Fine mapping to reduce the candidate region was conducted by selection of known microsatellite repeats from the ABI Linkage Mapping Panel version I (Applied Biosystems), the Todd Panel[13] and the Marshfield Linkage Maps. Further refinement was achieved by analysing novel microsatellites and single nucleotide polymorphisms (SNPs). Novel microsatellites were designed using the Human Genome Browser and Primer3 program.[14] Designed microsatellite markers were given a designation [human BAC accession number][microsatellite repeat unit][number of repeat units in the reference BAC], for example AL449425TA15.

SNPs were identified using the Human Genome Browser and sequenced using an ABI3730xl 96 capillary DNA Analyser (Applied Biosystems) with the ABI BigDye Terminator v3.1 (Applied Biosystems), to the manufacturer's specifications. Sequence was analysed using SeqMan II v5.06 software (DNASTAR Inc.) and BLAST 2.[15]

#### Results

A region of potential homozygosity was identified in all affected individuals on chromosome 9q34.2-34.3 between markers D9S164 and D9S2168. Further refinement suggested a common overlap at band q34.3 between markers D9S158 and D9S905 (Figure 2). Information regarding marker order was derived from analysis of the May 2004 freeze (HG17 assembly) of the Human Genome Browser.

Multipoint analysis provided further indication of linkage to this region. A fully penetrant autosomal recessive mode of inheritance and a disease gene frequency of 0.0001 were assumed. Due to the complexity of the family structure equal allele frequencies were assumed for each marker when calculating LOD scores. Pedigree allele inconsistencies were identified using PedCheck.[16] Multipoint analysis was performed using the GENEHUNTER v2.1 program[17] for markers in the region, with the highest LOD score of 5.64 between markers D9S158 and D9S905 (Figure 3).

Haplotype inspection after analysis of novel microsatellites and SNPs within this critical region also confirmed linkage and provided further refinement. The minimum critical region as defined by meiotic crossover events is bounded by rs3812547 at 136.5 Mb and rs2811742 at 137.0 Mb, a genetic distance of approximately 1 cM (Table 1).

	Genotype of Affected Individual														
Marker	IV:18	V:1	V:2	V:4	V:5	V:6	V:8	V:9	V:10	V:11	<b>VI:1</b>	<b>VI:2</b>	Marker Location (Mb)		
rs12684650	1-1	1-1	1-1	1-1	1-1	1-1	1-1	1-1	1-1	1-1	1-1	1-1	136.3		
rs3812547	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	<u>1-2</u>	<u>1-2</u>	2-2	2-2	136.5		
AL592301GCT9	1-1	1-1	1-1	1-1	1-1	1-1	1-1	1-1	1-1	1-1	1-1	1-1	136.6		
rs5901103	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	136.6		
rs2229974	2-2	2-2	2-2	2-2	2-2	2-2	-	2-2	2-2	2-2	2-2	2-2	136.7		
rs11574908	2-2	2-2	2-2	2-2	2-2	2-2	-	2-2	2-2	2-2	2-2	2-2	136.7		
rs10521	2-2	2-2	2-2	2-2	2-2	2-2	-	2-2	2-2	2-2	2-2	2-2	136.7		
rs3125000	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	136.7		
rs3124598	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	136.7		
rs3125004	2-2	2-2	2-2	2-2	2-2	2-2	-	-	2-2	2-2	2-2	-	136.7		
rs3124603	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	136.7		
rs3125006	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	136.7		
rs9411208	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	136.7		
rs4489420	2-2	2-2	2-2	2-2	2-2	2-2	-	2-2	2-2	2-2	2-2	2-2	136.7		
rs2811748	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	137.0		
rs2811744	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	137.0		
rs2811742	2-2	2-2	2-2	2-2	2-2	<u>1-2</u>	-	2-2	2-2	2-2	2-2	2-2	137.0		
rs4448378	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	137.1		
AL449425TA15	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-2	2-3	2-3	2-2	2-2	137.1		

#### DISCUSSION

We have studied 14 individuals from a single consanguineous pedigree. The number and age range of affected individuals within the family allow delineation of the clinical features and natural history of a new disorder, which we have termed MORM syndrome. The clinical diagnoses of mental retardation were based on assessment of adaptive functioning as it was not possible to conduct a formal IQ test. However, the assessment was conducted by a clinician experienced in the field of mental retardation that had a sound knowledge and understanding of the socio-cultural issues of the local population and was fluent in the local language. The name is derived from the principle findings; <u>M</u>ental retardation, truncal <u>O</u>besity, <u>R</u>etinal dystrophy and <u>M</u>icropenis.

There are similarities to Cohen syndrome, but the lack of characteristic facies, skin or gingival infection, microcephaly and "mottled retina" in the family allow clinical differentiation.[18] Bardet-Biedl syndrome is primarily characterised by a rod-cone dystrophy with visual problem onset at a mean age of 8.5y (100% over 9y), post axial polydactyly (69%), central obesity (72% of post pubertal), mental retardation (62%), hypogonadism (97% of males), and renal dysfunction; the figures in brackets being from a British clinical survey of cases.[19] Whilst the family would be diagnosable as having Bardet-Biedl using Beales' modified diagnostic criteria (rod-cone dystrophy, learning difficulties, obesity and male hypogonadism) age of onset and non-progressive nature of the visual impairment, and small penis without testicular anomalies are atypical.[19] In Bardet-Biedl type BBS5, reported only in

Newfoundland to date, a small penis is reported with no polydactyly; however, we have no evidence of linkage to this or to the other known BBS loci.[20]

We have shown linkage to this condition and a ~1 cM region of 9q34, with a maximum LOD score of 5.64. The minimum critical region contains a number of potential candidate genes that may cause MORM syndrome, including the cell surface neurogenic receptor Notch1 and KIAA0310, which is highly expressed in brain and testis. We experienced difficulties in identifying this locus. This was due to both the eventual small size of the critical region (which was to be expected given the number of affected individuals in the family) and the 9q34 sub-telomeric location (with an increased ratio of genetic to physical distance and a paucity of informative polymorphic markers). MORM syndrome appears to be phenotypically and genetically distinct from the Bardet-Biedl and Cohen syndromes, and is a further condition exhibiting obesity / mental retardation with which the clinician has to struggle!

#### Acknowledgements

We thank the family members and their physicians who helped with this study. DJH is supported by the Medical Research Council. KS, ER, HJ, JB and CGW are supported by the Wellcome Trust.

#### **Electronic-Database Information**

Online Mendelian Inheritance of Man (OMIM) for clinical and genetic information on Bardet-Biedl syndrome [209900] and Cohen syndrome [216550]: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM Genome Database (GDB) for polymorphic microsatellite data: http://gdbwww.gdb.org/gdb/ Human Genome Browser for loci, gene, polymorphic marker and SNP physical location data for the human genome: http://genome.cse.ucsc.edu/cgi-bin/hgGateway?org=human Center for Medical Genetics for the Marshfield Linkage Maps: http://research.marshfieldclinic.org/genetics/Map\_Markers/maps/IndexMapFrames.html Primer3 for design of novel microsatellite repeat markers: http://www-genome.wi.mit.edu/cgi-bin/primer/primer3\_www.cgi BLAST 2 for SNP sequence analysis: http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html

#### References

- American Psychiatric Association. *The Diagnostic and Statistical Manual of Mental Disorders (DSM IV)*. Washington DC: American Psychiatric Association, 1994.
- Mykytyn K, Nishimura DY, Searby CC, *et al.* Identification of the gene (BBS1) most commonly involved in Bardet-Biedl syndrome, a complex human obesity syndrome. *Nat Genet* 2002;**31**:435-438.

- Nishimura DY, Searby CC, Carmi R, *et al.* Positional cloning of a novel gene on chromosome 16q causing Bardet-Biedl syndrome (BBS2). *Hum Mol Genet* 2001;10:865-874.
- Young TL, Woods MO, Parfrey PS, *et al.* Canadian Bardet-Biedl syndrome family reduces the critical region of BBS3 (3p) and presents with a variable phenotype. *Am J Hum Genet* 1998;**78**:461-467.
- Mykytyn K, Braun T, Carmi R, *et al.* Identification of the gene that, when mutated, causes the human obesity syndrome BBS4. *Nat Genet* 2001;28:188-191.
- Young TL, Penney L, Woods MO, *et al.* A fifth locus for Bardet-Biedl syndrome maps to chromosome 2q31. *Am J Hum Genet* 1999;64:900-904.
- Slavotinek AM, Stone EM, Mykytyn K, *et al.* Mutations in MKKS cause Bardet-Biedl syndrome. *Nat Genet* 2000;26:15-16.
- Katsanis N, Beales PL, Woods MO, *et al.* Mutations in MKKS cause obesity, retinal dystrophy and renal malformations associated with Bardet-Biedl syndrome. *Nat Genet* 2000;26:67-70.
- Badano JL, Ansley SJ, Leitch CC, *et al.* Identification of a novel Bardet-Biedl syndrome protein, BBS7, that shares structural features with BBS1 and BBS2. *Am J Hum Genet* 2003;72:650-658.
- Ansley SJ, Badano JL, Blacque OE, *et al.* Basal body dysfunction is a likely cause of pleiotropic Bardet-Biedl syndrome. *Nature* 2003;425:628-633.
- Kolehmainen J, Norio R, Kivitie-Kallio S, *et al.* Refined mapping of the Cohen syndrome gene by linkage disequilibrium. *Eur J Hum Genet* 1997;**5**:206-213.

- Katsanis N. The oligogenic properties of Bardet-Biedl syndrome. *Hum Mol Genet* 2004;13:R65-R71.
- Reed PW, Davies JL, Copeman JB, *et al.* Chromosome-specific microsatellite sets for fluorescence-based, semi-automated genome mapping. *Nat Genet* 1994;7:390-395.
- Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. In: Misener S, Krawetz SA, eds. *Bioinformatics Methods and Protocols: Methods in Molecular Biology*. Totowa, NJ: Humana Press, 2000;365-386.
- 15. Tatusova TA, Madden TL. Blast 2 sequences a new tool for comparing protein and nucleotide sequences. *FEMS Microbiol Lett* 1999;**174**:247-250.
- O'Connell JR, Weeks DE. PedCheck: a program for identification of genotype incompatibilities in linkage analysis. *Am J Hum Genet* 1998;63:259-266.
- Kruglyak L, Daly MJ, Reeve-Daly MP, *et al.* Parametric and nonparametric linkage analysis: a unified multipoint approach. *Am J Hum Genet* 1996;**58**:1347-1363.
- Kivitie-Kallio S, Norio R. Cohen syndrome: essential features, natural history, and heterogeneity. *Am J Hum Genet* 2001;**102**:125-135.
- Beales PL, Elcioglu N, Woolf AS, *et al.* New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. *J Med Genet* 1999;**36**:437-446.
- Woods MO, Young TL, Parfrey PS, *et al.* Genetic heterogeneity of Bardet-Biedl syndrome in a distinct Canadian population: evidence for a fifth locus. *Genomics* 1999;55:2-9.

#### Figure 1

The figure shows three of the members of the pedigree affected with MORM syndrome, with mental retardation and reduced visual acuity. Dysmorphic features or congenital anomalies were not a feature.

### Figure 2

Pedigree of the reported family showing closest family links between parents of affected individuals. The majority of unaffected individuals have been omitted and only the closest consanguineous links between parents are shown. Disease phenotype for individuals with MORM syndrome is shown as filled in shapes. Shaded boxes denote regions of homozygosity in affected individuals subsequent to fine mapping.

### Figure 3

Multipoint analysis of the MORM family across the 9q34.2-34.3 region showing LOD score results for markers D9S164, D9S1818, D9S298, D9S312, D9S1826, D9S158, D9S905, D9S1838, and D9S2168.

# Table 1

The table shows the novel microsatellite markers and SNPs used in the study to confirm linkage to chromosome 9q34.3. The markers are listed centromere to qter in descending order. The affected individuals are referenced to Figure 2, showing the

family pedigree (affected individuals IV:3 and V:7 were not typed due to a lack of DNA). The genotype is given for each affected person for each marker. The meiotic crossovers in each affected are shown in bold / underlined. A dash signifies no result. The final column shows the physical location of each marker as derived from the Human Genome Browser.

Figure 1







. VI:1

# Table

	Genotype of Affected Subjects														
Microsatellite	IV:3	IV:18	V:1	V:2	V:3	V:5	V:6	V:7	V:8	V:9	V:10	V:11	<b>VI:1</b>	<b>VI:2</b>	Lod
D9S164	2/2	2/4	-	2/3	2/3	2/3	3/5	3/5	2/3	2/3	-	-	1/2	-	-10.75
D9S1818	1/1	1/1	1/1	1/2	1/2	1/1	1/3	1/3	1/1	1/1	-	-	1/1	-	-0.10
D9S298	2/2	1/2	2/2	2/2	2/2	1/2	1/2	1/2	1/2	1/2	1/2	1/2	-	-	-0.77
D9S312	4/4	2/4	4/4	1/4	1/4	2/4	1/4	1/4	2/4	2/4	4/4	-	2/4	-	0.67
D9S1826	2/2	2/2	2/2	2/2	2/2	2/2	1/2	1/2	2/2	2/2	2/2	2/2	2/2	-	2.84
D9S158	3/3	3/3	3/3	3/3	3/3	3/3	1/3	1/3	3/3	3/3	3/3	3/3	-	3/3	1.26
AL592301GCT9	-	-	-	1/1	-	-	1/1	1/1	-	-	-	-	1/1	-	
AL590226AC9	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	
AL449425TA15	-	2/2	2/2	2/2	2/2	2/2	2/2	2/2	2/2	2/2	2/3	2/3	2/2	2/2	3.52
D9S905	2/2	2/2	2/2	2/2	2/2	2/2	-	2/2	2/2	2/2	2/3	2/3	2/2	2/2	0.37
AL929554GT9	-	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	-	-	1/1	-	
AL929554CA9	-	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	-	-	1/1	-	
AL929554CCT9	-	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	-	-	1/1	-	
AL365502TTA9	-	-	1/1	1/1	-	-	1/1	1/1	-	-	-	-	1/1	-	
AL365502AAT13	-	1/2	2/2	2/2	2/2	1/2	2/2	2/2	2/2	2/2	-	-	2/2	-	
AL590627AC21	-	3/3	3/3	3/3	3/3	3/3	3/3	3/3	3/3	3/3	2/3	2/3	2/3	3/3	
D9S1838	-	3/3	3/3	3/3	3/3	3/3	3/3	3/3	3/3	3/3	2/3	-	3/3	3/3	1.44
D9S2168	-	1/2	1/2	1/2	1/2	1/2	1/2	1/2	1/2	1/2	1/2	1/2	1/2	1/2	-1.65